Can One Ebola Vaccine Help Against Another?

A licensed Ebola vaccine exists. The outbreak now spreading through Congo is caused by a different Ebola virus, and no vaccine is licensed for it. Can the first one help against the second?

In this episode, Emma and Ezra look at two peer-reviewed studies. A 2026 study in The Lancet by Halbrook, Rimoin, and colleagues followed just over a thousand people in Congo who received the licensed vaccine, and found antibodies that bind to a Bundibugyo virus protein, in different patterns in two cities. A 2025 study in Science Translational Medicine by Mdluli, Rolland, and colleagues tested a different vaccine and found essentially no meaningful binding to that protein. Both measure antibodies in blood, not whether anyone is protected. Along the way: why “sticking” isn’t “blocking,” what an optimist and a realist each take from the data, and the comparison that would settle it.

This episode is about research, not medical advice.

This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.

What to take away
  • What the studies support: some vaccinated people in Congo had antibodies that bound to a Bundibugyo protein, in different patterns in two cities, while a second study of a different vaccine found essentially no meaningful binding.
  • What they can’t tell us: whether any vaccine protects anyone against Bundibugyo. Both studies measure antibodies in blood, not illness, and the first has no unvaccinated comparison group.
  • A question for any headline: are they measuring antibodies, or measuring illness?

For practitioners and policymakers
  • Antibody reactivity on a blood test is not a protection test. What answers the question is a comparison group, followed for infection, plus tests of whether antibodies can neutralize the actual virus.
  • A neutral question to ask of any proposal: will anyone track the outcomes, and is there a group to compare against?
  • A trial that includes the licensed vaccine started in Congo in October; the studies here can’t say what it will find.
  • This episode is research, not medical advice, and it makes no recommendation about who should or shouldn’t be vaccinated.

The research
Primary paper (licensed vaccine, Congo). Halbrook, M., Merritt, S., Hoff, N. A., Mukadi, P., Kompany, J. P., Musene, K., … Rimoin, A. W. (2026). Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: A longitudinal cohort study. The Lancet, 408(10559), 1019–1028. https://doi.org/10.1016/S0140-6736(26)01608-9
  • Access: open access.
  • Found: antibodies that bind to a Bundibugyo protein appeared in about half of vaccinated people in Beni and in about one in three in Mbandaka at one later visit, and the patterns differed. Limit: it measured binding only, with no unvaccinated comparison group, so it can’t say the vaccine caused the pattern or protects.

Companion paper (a different vaccine, trial volunteers). Mdluli, T., Wollen-Roberts, S., Merbah, M., … Rolland, M. (2025). Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses. Science Translational Medicine, 17(792), Article eadq2496. https://doi.org/10.1126/scitranslmed.adq2496
  • Access: closed access (subscription or library login). We didn’t find a legal free version; the abstract is indexed in PubMed (PMID 40173257).
  • Found: after two doses of Janssen’s Ebola vaccine, antibodies were mostly specific to the Zaire protein, with essentially no meaningful binding to Bundibugyo. Limit: a different vaccine and lab method, trial volunteers rather than outbreak-affected communities, and funding from the vaccine’s manufacturer.

The two studies use different vaccines, people, and lab methods, so their numbers shouldn’t be compared side by side.

In the news

The fine print
  • The first study measured antibody binding only. It had no comparison group, couldn’t verify who was vaccinated, and more than a third of people in one city dropped out over five years.
  • The second study used a different vaccine, trial volunteers, a stand-in virus rather than live virus, and in some groups a short gap between doses that the authors say may have limited cross-reactions. It was funded by the vaccine’s manufacturer.
  • What would settle it: trials that compare vaccinated and unvaccinated people and track who gets sick, plus tests of whether antibodies neutralize the actual virus.
  • Outbreak numbers change by the week. Check the CDC page for current figures.

Credits
  • Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).
  • Outro music: created with Eleven Music.
  • Website: frompeertoear.com
  • Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.

Can One Ebola Vaccine Help Against Another?
Broadcast by